The Future of Pharma: AI in Drug Research, Quality & Regulatory Affairs

Join us to discuss the role of AI in Drug Research, Quality & Regulatory Affairs

Artificial Intelligence is revolutionizing the pharmaceutical industry—accelerating drug discovery, optimizing quality assurance, and reshaping regulatory processes.

This event, co-organised by The French Chamber of Commerce and The Singaporean-German Chamber of Industry and Commerce, will bring together experts across R&D, manufacturing, and regulatory affairs to explore how AI is being used to drive innovation, ensure compliance, and improve patient outcomes.

Key topics will include:

• AI in Drug Discovery & Development: Target identification, predictive modeling, and AI-driven clinical trial design
• AI in Quality Assurance & Manufacturing: Real-time monitoring, automated inspection, and process optimization
• AI in Regulatory Affairs: Regulatory perspectives on AI/ML, intelligent submission preparation, and audit readiness
• Data Integrity & Model Governance: Ensuring data quality, model validation, and ethical AI use
• Case Studies & Future Trends: Real-world success stories and the evolving role of AI in personalized medicine

Whether you're in pharma, biotech, quality, or regulatory affairs, this event will offer actionable insights to help you leverage AI across the drug development lifecycle—safely, effectively, and compliantly.

Speakers

• Karin Markgraf, Head of Regulatory Affairs Asia Pacific at Merck Group
• Damien Keogh, Founder at BlueMaiden Biosciences
• more speakers to be announced

Moderator

• Maximilian Englisch, Global Vice-President of Sales at WALDNER Group

Modalités d'accès